Table 1. Demographic and Treatment Characteristics of Patients.
| Characteristic | Patients, No. (%) | P value | ||
|---|---|---|---|---|
| CMT (n = 154) | Auto-SCT (n = 116) | Allo-SCT (n = 279) | ||
| Age, median (range), y | 47 (14-60) | 33.5 (15-60) | 35 (14-60) | <.001 |
| Sex | ||||
| Male | 85 (55.2) | 74 (63.8) | 155 (55.6) | .27 |
| Female | 69 (44.8) | 42 (36.2) | 124 (44.4) | |
| WBC count, median (range), /µL | 19 400 (800-407 000) | 21 400 (1900-325 000) | 20 300 (600-376 300) | .73 |
| First induction therapy | ||||
| DA | 42 (27.3) | 29 (25.0) | 60 (21.5) | .34 |
| IA | 89 (57.8) | 70 (60.3) | 188 (67.4) | |
| Other | 23 (14.9) | 17 (14.7) | 31 (11.1) | |
| Second induction therapy or first consolidation therapy | ||||
| DA | 14 (9.1) | 8 (6.9) | 16 (5.7) | .81 |
| IA | 14 (9.1) | 13 (11.2) | 21 (7.5) | |
| 3 + 3 | 48 (31.2) | 31 (26.7) | 80 (28.7) | |
| Intermediate- or high-dose cytarabine | 68 (44.2) | 56 (48.3) | 144 (51.6) | |
| Others | 10 (6.5) | 8 (6.9) | 18 (6.5) | |
| No. of cycles of consolidation chemotherapy, median (range) | 4 (3-7) | 3 (3-5) | 2 (1-4) | NA |
| Duration from CR1 to transplant, median (range), mo | NA | 5.9 (5.4-9.6) | 3.9 (2.8-7.7) | <.001 |
| No. of cycles to CR | ||||
| 1 | 126 (81.8) | 97 (83.6) | 217 (77.8) | .34 |
| 2 | 28 (18.2) | 19 (16.4) | 62 (22.2) | |
| MRD1 | ||||
| Positive | 81 (52.6) | 64 (55.2) | 215 (77.1) | <.001 |
| Negative | 73 (47.4) | 52 (44.8) | 64 (22.9) | |
| MRD2 | ||||
| Positive | 52 (33.8) | 33 (28.4) | 132 (47.3) | .001 |
| Negative | 102 (66.2) | 83 (71.6) | 147 (52.7) | |
| MRD3 | ||||
| Positive | 39 (25.3) | 26 (22.4) | 105 (37.6) | .002 |
| Negative | 115 (74.7) | 90 (77.6) | 174 (62.4) | |
Abbreviations: 3 + 3, daunorubicin hydrochloride or idarubicin hydrochloride, 10 mg/m2 per day, on days 1 to 3 and cytarabine, 2.0 g/m2 twice daily, on days 1 to 3; allo-SCT, allogeneic stem cell transplant; auto-SCT, autologous stem cell transplant; CMT, chemotherapy; CR, complete remission; CR1, first CR; DA, daunorubicin hydrochloride and cytarabine; IA, idarubicin hydrochloride and cytarabine; MRD1, measurable residual disease after 1 course of CMT; MRD2, measurable residual disease after 2 courses of CMT; MRD3, measurable residual disease after 3 courses of CMT; NA, not applicable.
SI conversion factor: To convert WBC to ×109 per liter, multiply by 0.001.